{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}],"title":"Complete Response, Very Good Partial Response, or Partial Response"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Stable Disease or Progressive Disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Number of patients with hematologic complete response (CR), very good partial response (VGPR), or partial response (PR).\n\nPer protocol, a hematologic CR is defined as negative serum and urine immunofixation electrophoresis with normal serum free light chain ratio; a VGPR is reduction in the dFLC\\* to \\<40 mg/L; and a PR is dFLC reduction by \\>50%.\n\n\\* \"dFLC\" is difference in involved and uninvolved serum free light-chain levels","groups":[{"description":"Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month for up to 24 total cycles.\n\nDaratumumab: Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression, inability to tolerate, or 24 cycles completed.","id":"OG000","title":"Daratumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3 months","title":"Assess Hematologic Response Based on Blood and Urine Testing Using Standard Criteria","type":"SECONDARY","unitOfMeasure":"Participants"}